LNTH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LNTH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-05-01), Lantheus Holdings's current share price is $67.73. Lantheus Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 was $1.50. Lantheus Holdings's Cyclically Adjusted Price-to-FCF for today is 45.15.
The historical rank and industry rank for Lantheus Holdings's Cyclically Adjusted Price-to-FCF or its related term are showing as below:
During the past years, Lantheus Holdings's highest Cyclically Adjusted Price-to-FCF was 114.93. The lowest was 35.25. And the median was 62.68.
LNTH's Cyclically Adjusted Price-to-FCF is ranked worse thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Lantheus Holdings's adjusted free cash flow per share data for the three months ended in Dec. 2023 was $1.429. Add all the adjusted free cash flow per share for the past 10 years together and divide 10 will get our Cyclically Adjusted FCF per Share, which is $1.50 for the trailing ten years ended in Dec. 2023.
The historical data trend for Lantheus Holdings's Cyclically Adjusted Price-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
Cyclically Adjusted Price-to-FCF | Get a 7-Day Free Trial | 52.32 | 71.89 | 70.80 | 52.45 | 41.33 |
For the Drug Manufacturers - Specialty & Generic subindustry, Lantheus Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, Lantheus Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Lantheus Holdings's Cyclically Adjusted Price-to-FCF falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.
Lantheus Holdings's Cyclically Adjusted Price-to-FCF for today is calculated as
Cyclically Adjusted Price-to-FCF | = | Share Price | / | Cyclically Adjusted FCF per Share |
= | 67.73 | / | 1.5 | |
= | 45.15 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lantheus Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2023 is calculated as:
For example, Lantheus Holdings's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2023 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 1.429 | / | 129.4194 | * | 129.4194 | |
= | 1.429 |
Current CPI (Dec. 2023) = 129.4194.
Lantheus Holdings Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201403 | -0.084 | 99.695 | -0.109 |
201406 | -0.256 | 100.560 | -0.329 |
201409 | 1.034 | 100.428 | 1.332 |
201412 | -0.371 | 99.070 | -0.485 |
201503 | 0.634 | 99.621 | 0.824 |
201506 | -0.744 | 100.684 | -0.956 |
201509 | 0.101 | 100.392 | 0.130 |
201512 | 0.259 | 99.792 | 0.336 |
201603 | 0.070 | 100.470 | 0.090 |
201606 | 0.553 | 101.688 | 0.704 |
201609 | 0.397 | 101.861 | 0.504 |
201612 | 0.276 | 101.863 | 0.351 |
201703 | 0.016 | 102.862 | 0.020 |
201706 | 0.441 | 103.349 | 0.552 |
201709 | 0.315 | 104.136 | 0.391 |
201712 | 0.185 | 104.011 | 0.230 |
201803 | -0.071 | 105.290 | -0.087 |
201806 | 0.372 | 106.317 | 0.453 |
201809 | 0.489 | 106.507 | 0.594 |
201812 | 0.251 | 105.998 | 0.306 |
201903 | -0.002 | 107.251 | -0.002 |
201906 | 0.438 | 108.070 | 0.525 |
201909 | 0.574 | 108.329 | 0.686 |
201912 | 0.441 | 108.420 | 0.526 |
202003 | 0.167 | 108.902 | 0.198 |
202006 | -0.102 | 108.767 | -0.121 |
202009 | 0.072 | 109.815 | 0.085 |
202012 | -0.048 | 109.897 | -0.057 |
202103 | 0.108 | 111.754 | 0.125 |
202106 | 0.344 | 114.631 | 0.388 |
202109 | 0.028 | 115.734 | 0.031 |
202112 | 0.138 | 117.630 | 0.152 |
202203 | 0.101 | 121.301 | 0.108 |
202206 | 0.964 | 125.017 | 0.998 |
202209 | 1.231 | 125.227 | 1.272 |
202212 | 1.424 | 125.222 | 1.472 |
202303 | 1.466 | 127.348 | 1.490 |
202306 | -0.605 | 128.729 | -0.608 |
202309 | 1.458 | 129.860 | 1.453 |
202312 | 1.429 | 129.419 | 1.429 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.
Thank you for viewing the detailed overview of Lantheus Holdings's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Andrea Sabens | officer: Chief Accounting Officer | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Marshall Robert J. Jr. | officer: CFO and Treasurer | C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Paul Blanchfield | officer: Chief Commercial Officer | C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862 |
Mary Anne Heino | director, officer: CEO and President | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862 |
Daniel Niedzwiecki | officer: See Remarks | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Minnie Baylor-henry | director | C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803 |
Etienne Montagut | officer: See Remarks | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Sam R Leno | director | C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760 |
Brian A Markison | director | 501 FIFTH STREET, BRISTOL TN 37620 |
Jean-claude Provost | officer: Chief Medical Officer | C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730 |
Julie Mchugh | director | C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110 |
Gerard Ber | director | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Carol Walker | officer: Senior Vice President, Quality | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
Ying Vivian Yao | officer: Chief Human Resources Officer | C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
John J. Bolla | director | C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862 |
From GuruFocus
By GuruFocus Research GuruFocus Editor • 05-18-2023
By sperokesalga sperokesalga • 03-17-2023
By sperokesalga sperokesalga • 06-12-2023
By sperokesalga sperokesalga • 06-01-2023
By sperokesalga sperokesalga • 02-09-2023
By Stock market mentor Stock market mentor • 02-06-2023
By Nathan Aisenstadt • 12-17-2023
By Stock market mentor Stock market mentor • 01-04-2023
By GuruFocus Research • 10-30-2023
By Marketwired • 08-03-2023